"COMCO suspects that manufacturers and distributors of the active
pharmaceutical ingredient Scopolamine Butylbromide have concluded
unlawful price and market sharing agreements," the agency said.
"There are reasonable grounds to suspect that the undertakings have
kept the prices of this pharmaceutical ingredient high and that they
have allocated markets. The investigation shall examine whether
there are indeed unlawful restrictions of competition."
[to top of second column] |
COMCO declined to name the makers of the drug ingredients, but said
domestic and foreign companies were under scrutiny.
(Reporting by John Miller)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |